Key Highlights

  • A three-year partnership with US-listed IonQ and a fresh capital raise have pushed Archer Materials, one of the ASX's few pure-play quantum names, back onto retail investors' radar in mid-2026.
  • On 30 June 2026 the Adelaide- and Sydney-based company announced a three-year collaboration with US-listed quantum computing group IonQ, and days later it moved to strengthen its balance sheet through a placement and a share purchase plan (SPP).
  • Under the deal announced on 30 June 2026, Archer will pay IonQ US$250,000 on signing and a further US$250,000 every six months — roughly US$1.5 million over the three-year term, which is renewable by agreement.
  • Archer cites an industry estimate of a potential A$6 billion-a-year domestic quantum market by 2045 — a forward-looking, third-party projection rather than a company forecast.

A three-year partnership with US-listed IonQ and a fresh capital raise have pushed Archer Materials, one of the ASX's few pure-play quantum names, back onto retail investors' radar in mid-2026.

Company Overview

Archer describes itself as "Australia's only listed pure-play quantum hardware company." Its flagship program is the 12CQ chip, an effort to build a quantum bit (qubit) from carbon-based materials with the long-term ambition of more practical quantum computing and advanced sensing. Alongside it, Archer is developing a graphene-based biochip aimed at rapid potassium blood testing, a marker relevant to kidney disease. A third strand applies quantum machine learning (QML) to problems such as financial fraud detection.

Recent Developments

Archer Materials (ASX: AXE) has generated more headlines in the past month than it has for some time. On 30 June 2026 the Adelaide- and Sydney-based company announced a three-year collaboration with US-listed quantum computing group IonQ, and days later it moved to strengthen its balance sheet through a placement and a share purchase plan (SPP). For a pre-revenue deep-tech developer whose shares can move sharply on news, the combination has reignited debate about whether the "quantum story" is regaining momentum.

Financial and Operational Snapshot

As at 31 March 2026, Archer reported cash of A$10.3 million and no debt, with operating cash flow of positive A$139,000 for that quarter — an unusual result for a pre-revenue business, and one the company did not attribute to a specific cause in the material reviewed.

What May Be Watched Next

Near-term markers include delivery of the biochip beta prototype and any move toward clinical trials or a licensing agreement; a full QML fraud-detection prototype the company has flagged for around end-2026; further readout milestones on the 12CQ chip; and progress on the IonQ feasibility work. Each is a potential re-rating point — and, equally, a potential disappointment if timelines slip.

Key Risks

The risks are those typical of pre-revenue deep-tech. Archer must fund ongoing research from cash reserves, and repeated raises dilute existing holders. Commercial timelines are long and uncertain, technical hurdles in quantum hardware are formidable, and there is no guarantee the 12CQ chip or biochip reaches market. The IonQ deal is a multi-year cost commitment, not a revenue stream, and competition across quantum is intense. Forward-looking statements about markets and prototypes should be treated with caution.

What does Archer Materials (ASX do?

Archer describes itself as "Australia's only listed pure-play quantum hardware company." Its flagship program is the 12CQ chip, an effort to build a quantum bit (qubit) from carbon-based materials with the long-term ambition of more…

What is the latest development?

Archer Materials (ASX: AXE) has generated more headlines in the past month than it has for some time. On 30 June 2026 the Adelaide- and Sydney-based company announced a three-year collaboration with US-listed quantum computing…

What financial or operational point stands out?

As at 31 March 2026, Archer reported cash of A$10.3 million and no debt, with operating cash flow of positive A$139,000 for that quarter — an unusual result for a pre-revenue business, and one the…

What may be watched next?

Near-term markers include delivery of the biochip beta prototype and any move toward clinical trials or a licensing agreement; a full QML fraud-detection prototype the company has flagged for around end-2026; further readout milestones on…